Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity
Human leukocyte antigen (HLA) proteins are present at the cellular surface of antigen-presenting cells and play a crucial role in the adaptive immune response. Class I genes, specifically certain HLA-B alleles, are associated with adverse drug reactions (ADRs) and are used as pharmacogenetic markers...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.891838/full |
| _version_ | 1811314184378384384 |
|---|---|
| author | Mohammed Dashti Abdullah Al-Matrouk Arshad Channanath Prashantha Hebbar Fahd Al-Mulla Thangavel Alphonse Thanaraj |
| author_facet | Mohammed Dashti Abdullah Al-Matrouk Arshad Channanath Prashantha Hebbar Fahd Al-Mulla Thangavel Alphonse Thanaraj |
| author_sort | Mohammed Dashti |
| collection | DOAJ |
| description | Human leukocyte antigen (HLA) proteins are present at the cellular surface of antigen-presenting cells and play a crucial role in the adaptive immune response. Class I genes, specifically certain HLA-B alleles, are associated with adverse drug reactions (ADRs) and are used as pharmacogenetic markers. Although ADRs are a common causes of hospitalization and mortality, the data on the prevalence of HLA-B pharmacogenetics markers in Arab countries are scarce. In this study, we investigated the frequencies of major HLA-B pharmacogenomics markers in the Qatari population. Next-generation sequencing data from 1,098 Qatari individuals were employed for HLA-B typing using HLA-HD version 1.4.0 and IPD-IMGT/HLA database. In addition, HLA-B pharmacogenetics markers were obtained from the HLA Adverse Drug Reaction Database. In total, 469 major HLA-B pharmacogenetic markers were identified, with HLA-B*51:01 being the most frequent pharmacogenetic marker (26.67%) in the Qatari population. Moreover, HLA-B*51:01 is associated with phenytoin- and clindamycin-induced ADRs. The second most frequent pharmacogenetic marker was the HLA-B*58:01 allele (6.56%), which is associated with allopurinol-induced ADRs. The third most frequent pharmacogenetic marker was the HLA-B*44:03 allele, which is associated with phenytoin-induced ADRs. The establishment of a pharmacogenetics screening program in Qatar for cost effective interventions aimed at preventing drug-induced hypersensitivity can be aided by the highly prevalent HLA-B pharmacogenetic markers detected here. |
| first_indexed | 2024-04-13T11:08:45Z |
| format | Article |
| id | doaj.art-403b0e6bb29f4e4f85437e879143fdd6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T11:08:45Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-403b0e6bb29f4e4f85437e879143fdd62022-12-22T02:49:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.891838891838Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug HypersensitivityMohammed Dashti0Abdullah Al-Matrouk1Arshad Channanath2Prashantha Hebbar3Fahd Al-Mulla4Thangavel Alphonse Thanaraj5Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, KuwaitNarcotic and Psychotropic Department, Ministry of Interior, Farwaniya, KuwaitGenetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, KuwaitGenetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, KuwaitGenetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, KuwaitGenetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, KuwaitHuman leukocyte antigen (HLA) proteins are present at the cellular surface of antigen-presenting cells and play a crucial role in the adaptive immune response. Class I genes, specifically certain HLA-B alleles, are associated with adverse drug reactions (ADRs) and are used as pharmacogenetic markers. Although ADRs are a common causes of hospitalization and mortality, the data on the prevalence of HLA-B pharmacogenetics markers in Arab countries are scarce. In this study, we investigated the frequencies of major HLA-B pharmacogenomics markers in the Qatari population. Next-generation sequencing data from 1,098 Qatari individuals were employed for HLA-B typing using HLA-HD version 1.4.0 and IPD-IMGT/HLA database. In addition, HLA-B pharmacogenetics markers were obtained from the HLA Adverse Drug Reaction Database. In total, 469 major HLA-B pharmacogenetic markers were identified, with HLA-B*51:01 being the most frequent pharmacogenetic marker (26.67%) in the Qatari population. Moreover, HLA-B*51:01 is associated with phenytoin- and clindamycin-induced ADRs. The second most frequent pharmacogenetic marker was the HLA-B*58:01 allele (6.56%), which is associated with allopurinol-induced ADRs. The third most frequent pharmacogenetic marker was the HLA-B*44:03 allele, which is associated with phenytoin-induced ADRs. The establishment of a pharmacogenetics screening program in Qatar for cost effective interventions aimed at preventing drug-induced hypersensitivity can be aided by the highly prevalent HLA-B pharmacogenetic markers detected here.https://www.frontiersin.org/articles/10.3389/fphar.2022.891838/fullHLA-B allelespharmacogeneticsdrug hypersensitivityHLA typing class IQatari population |
| spellingShingle | Mohammed Dashti Abdullah Al-Matrouk Arshad Channanath Prashantha Hebbar Fahd Al-Mulla Thangavel Alphonse Thanaraj Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity Frontiers in Pharmacology HLA-B alleles pharmacogenetics drug hypersensitivity HLA typing class I Qatari population |
| title | Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity |
| title_full | Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity |
| title_fullStr | Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity |
| title_full_unstemmed | Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity |
| title_short | Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity |
| title_sort | distribution of hla b alleles and haplotypes in qatari recommendation for establishing pharmacogenomic markers screening for drug hypersensitivity |
| topic | HLA-B alleles pharmacogenetics drug hypersensitivity HLA typing class I Qatari population |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.891838/full |
| work_keys_str_mv | AT mohammeddashti distributionofhlaballelesandhaplotypesinqatarirecommendationforestablishingpharmacogenomicmarkersscreeningfordrughypersensitivity AT abdullahalmatrouk distributionofhlaballelesandhaplotypesinqatarirecommendationforestablishingpharmacogenomicmarkersscreeningfordrughypersensitivity AT arshadchannanath distributionofhlaballelesandhaplotypesinqatarirecommendationforestablishingpharmacogenomicmarkersscreeningfordrughypersensitivity AT prashanthahebbar distributionofhlaballelesandhaplotypesinqatarirecommendationforestablishingpharmacogenomicmarkersscreeningfordrughypersensitivity AT fahdalmulla distributionofhlaballelesandhaplotypesinqatarirecommendationforestablishingpharmacogenomicmarkersscreeningfordrughypersensitivity AT thangavelalphonsethanaraj distributionofhlaballelesandhaplotypesinqatarirecommendationforestablishingpharmacogenomicmarkersscreeningfordrughypersensitivity |